Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2003-07-01
Target enrollment:
Participant gender:
Summary
The folate receptor (FR) is overexpressed by many different cancer types, including renal
cell carcinoma. Besides helping in the diagnosis of cancer, a folate-targeted imaging agent
could provide an effective method to identify folate receptor-positive (FR+) cancer patients
that may benefit from folate-targeted therapy. Up to 40 subjects, with known or strongly
suspected metastatic renal cell carcinoma with at least one target lesion detected by a
diagnostic imaging procedure (e.g. ultrasonography, CT, or MRI), will be enrolled in this
study.